Lung Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By Region
The global lung cancer therapeutics market is projected to witness impressive growth during the forecast period. The factors contributing to the growth of the market are the increasing incidence of lung cancer and sophisticated treatments associated with lung cancer.
Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer, which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of the high proliferation of cancer cells in the lungs.
The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines is expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.
Increasing Prevalence of Lung Cancer
Lung cancer (both small cell and non-small cell) is the second most common cancer globally. As per the American Cancer Society’s estimates for lung cancer in 2022, approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) were reported in the US, and about 130,180 (68,820 men and 61,360 women) people died due to lung cancer. Further, the overall chances of lung cancer prevalence in a man for a lifetime period are 1 in 15, and for women, the risk is about 1 in 17. This number includes smokers as we non-smokers.
The rise in demand for Immunotherapy
The use of medications, vaccinations, and other therapies to stimulate the immune system's natural defenses so that it can combat cancer is known as immunotherapy. One class of immunotherapy medication known as 'anti-PD-1' has been demonstrated to result in significant tumor regression in 25% of patients who get it after a round of chemotherapy. Three immunotherapy drugs—pembrolizumab, atezolizumab, and nivolumab have been approved to treat certain non-small cell lung cancers. Additionally, several organizations are funding immunotherapy research, which is anticipated to boost market expansion. For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers. Hence, rising investment and adoption of immunotherapy are fueling the demand for the global lung cancer therapeutics market.
Side Effects of cancer treatment
Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.
Market Segmentation
The global lung cancer therapeutics market is segmented based on cancer cell type, treatment, region, and company. Based on Cancer Cell Type, the market is categorized into Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC). Based on Treatment, the market is segmented into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other Treatments.
Recent Developments
AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.
Report Scope:
In this report, the global lung cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer, which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of the high proliferation of cancer cells in the lungs.
The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines is expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.
Increasing Prevalence of Lung Cancer
Lung cancer (both small cell and non-small cell) is the second most common cancer globally. As per the American Cancer Society’s estimates for lung cancer in 2022, approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) were reported in the US, and about 130,180 (68,820 men and 61,360 women) people died due to lung cancer. Further, the overall chances of lung cancer prevalence in a man for a lifetime period are 1 in 15, and for women, the risk is about 1 in 17. This number includes smokers as we non-smokers.
The rise in demand for Immunotherapy
The use of medications, vaccinations, and other therapies to stimulate the immune system's natural defenses so that it can combat cancer is known as immunotherapy. One class of immunotherapy medication known as 'anti-PD-1' has been demonstrated to result in significant tumor regression in 25% of patients who get it after a round of chemotherapy. Three immunotherapy drugs—pembrolizumab, atezolizumab, and nivolumab have been approved to treat certain non-small cell lung cancers. Additionally, several organizations are funding immunotherapy research, which is anticipated to boost market expansion. For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers. Hence, rising investment and adoption of immunotherapy are fueling the demand for the global lung cancer therapeutics market.
Side Effects of cancer treatment
Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.
Market Segmentation
The global lung cancer therapeutics market is segmented based on cancer cell type, treatment, region, and company. Based on Cancer Cell Type, the market is categorized into Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC). Based on Treatment, the market is segmented into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other Treatments.
Recent Developments
- In March 2019, AdoRx Treatments Limited announced a strategic alliance with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson (LCI) for the creation of brand-new, innovative lung cancer therapeutics.
AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.
Report Scope:
In this report, the global lung cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Lung Cancer Therapeutics Market, By Cancer Cell Type:
- Non-small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Lung Cancer Therapeutics Market, By Treatment:
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Other Treatments
- Lung Cancer Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. SERVICE OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
5.3.1. By Cancer Cell Type
5.3.2. By Treatment
6. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Cancer Cell Type
6.3.1.2.2. By Treatment
6.3.2. Canada Lung Cancer Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Cancer Cell Type
6.3.2.2.2. By Treatment
6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Cancer Cell Type
6.3.3.2.2. By Treatment
7. EUROPE LUNG CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Lung Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Cancer Cell Type
7.3.1.2.2. By Treatment
7.3.2. Germany Lung Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Cancer Cell Type
7.3.2.2.2. By Treatment
7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Cancer Cell Type
7.3.3.2.2. By Treatment
7.3.4. Italy Lung Cancer Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Cancer Cell Type
7.3.4.2.2. By Treatment
7.3.5. Spain Lung Cancer Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Cancer Cell Type
7.3.5.2.2. By Treatment
8. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Lung Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Cancer Cell Type
8.3.1.2.2. By Treatment
8.3.2. Japan Lung Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Cancer Cell Type
8.3.2.2.2. By Treatment
8.3.3. India Lung Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Cancer Cell Type
8.3.3.2.2. By Treatment
8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Cancer Cell Type
8.3.4.2.2. By Treatment
8.3.5. Australia Lung Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Cancer Cell Type
8.3.5.2.2. By Treatment
9. SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Cancer Cell Type
9.3.1.2.2. By Treatment
9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Cancer Cell Type
9.3.2.2.2. By Treatment
9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Cancer Cell Type
9.3.3.2.2. By Treatment
10. MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Lung Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Cancer Cell Type
10.3.1.2.2. By Treatment
10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Cancer Cell Type
10.3.2.2.2. By Treatment
10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Cancer Cell Type
10.3.3.2.2. By Treatment
10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Cancer Cell Type
10.3.4.2.2. By Treatment
10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Cancer Cell Type
10.3.5.2.2. By Treatment
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Increasing Prevalence of Lung Cancer.
11.1.2. Rise in the number of Tobacco Smokers
11.1.3. Rise in demand for Immunotherapy
11.2. Challenges
11.2.1. High Cost of Cancer Treatment
11.2.2. Side Effects of Drugs
11.2.3. Lack of skilled workforce
12. MARKET TRENDS & DEVELOPMENTS
12.1. Product Launches
12.2. Mergers & Acquisitions
12.3. Technological Advancements
13. CLINICAL TRIAL ANALYSIS
14. GLOBAL LUNG CANCER THERAPEUTICS MARKET: SWOT ANALYSIS
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (In Case of Listed Companies)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. AstraZeneca Plc
15.6.2. Boehringer Ingelheim International GmbH.
15.6.3. Bristol-Myers Squibb Company
15.6.4. Eli Lilly and Company
15.6.5. F. Hoffmann-La Roche Ltd.
15.6.6. Merck & Co
15.6.7. Pfizer Inc.
15.6.8. Allergan Inc.
15.6.9. Teva Pharmaceutical Industries Ltd.
15.6.10. Abbvie, Inc.
15.6.11. Johnson & Johnson
15.6.12. Amgen Inc.
15.6.13. Novartis AG
16. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
5.3.1. By Cancer Cell Type
5.3.2. By Treatment
6. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Cancer Cell Type
6.3.1.2.2. By Treatment
6.3.2. Canada Lung Cancer Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Cancer Cell Type
6.3.2.2.2. By Treatment
6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Cancer Cell Type
6.3.3.2.2. By Treatment
7. EUROPE LUNG CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Lung Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Cancer Cell Type
7.3.1.2.2. By Treatment
7.3.2. Germany Lung Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Cancer Cell Type
7.3.2.2.2. By Treatment
7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Cancer Cell Type
7.3.3.2.2. By Treatment
7.3.4. Italy Lung Cancer Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Cancer Cell Type
7.3.4.2.2. By Treatment
7.3.5. Spain Lung Cancer Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Cancer Cell Type
7.3.5.2.2. By Treatment
8. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Lung Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Cancer Cell Type
8.3.1.2.2. By Treatment
8.3.2. Japan Lung Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Cancer Cell Type
8.3.2.2.2. By Treatment
8.3.3. India Lung Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Cancer Cell Type
8.3.3.2.2. By Treatment
8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Cancer Cell Type
8.3.4.2.2. By Treatment
8.3.5. Australia Lung Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Cancer Cell Type
8.3.5.2.2. By Treatment
9. SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Cancer Cell Type
9.3.1.2.2. By Treatment
9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Cancer Cell Type
9.3.2.2.2. By Treatment
9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Cancer Cell Type
9.3.3.2.2. By Treatment
10. MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Lung Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Cancer Cell Type
10.3.1.2.2. By Treatment
10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Cancer Cell Type
10.3.2.2.2. By Treatment
10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Cancer Cell Type
10.3.3.2.2. By Treatment
10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Cancer Cell Type
10.3.4.2.2. By Treatment
10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Cancer Cell Type
10.3.5.2.2. By Treatment
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Increasing Prevalence of Lung Cancer.
11.1.2. Rise in the number of Tobacco Smokers
11.1.3. Rise in demand for Immunotherapy
11.2. Challenges
11.2.1. High Cost of Cancer Treatment
11.2.2. Side Effects of Drugs
11.2.3. Lack of skilled workforce
12. MARKET TRENDS & DEVELOPMENTS
12.1. Product Launches
12.2. Mergers & Acquisitions
12.3. Technological Advancements
13. CLINICAL TRIAL ANALYSIS
14. GLOBAL LUNG CANCER THERAPEUTICS MARKET: SWOT ANALYSIS
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (In Case of Listed Companies)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. AstraZeneca Plc
15.6.2. Boehringer Ingelheim International GmbH.
15.6.3. Bristol-Myers Squibb Company
15.6.4. Eli Lilly and Company
15.6.5. F. Hoffmann-La Roche Ltd.
15.6.6. Merck & Co
15.6.7. Pfizer Inc.
15.6.8. Allergan Inc.
15.6.9. Teva Pharmaceutical Industries Ltd.
15.6.10. Abbvie, Inc.
15.6.11. Johnson & Johnson
15.6.12. Amgen Inc.
15.6.13. Novartis AG
16. STRATEGIC RECOMMENDATIONS
